Literature DB >> 2291664

Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

E Matthes1, P Langen, M von Janta-Lipinski, H Will, H C Schröder, H Merz, B E Weiler, W E Müller.   

Abstract

2',3'-Dideoxy-3'-fluorothymidine (FddThd), 2',3'-didehydro-2',3'- dideoxythymidine (ddeThd), and 3'-fluoro-5-methyl-deoxycytidine (FddMeCyt) are, in their triphosphate forms, selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. We report that 0.3 microM FddThd, FddMeCyt, or ddeThd as well as 3'-chloro-5-methyl-deoxycytidine (ClddMeCyt) or 3'-amino-5-methyl-deoxycytidine (AddMeCyt) almost completely blocked production of hepatitis B virus (HBV) particles by HBV DNA-transfected cell line 2.2.15 in vitro. Only at an at least 10-fold-higher concentration was a cytotoxic effect observed. These results indicate that FddThd, FddMeCyt, ClddMeCyt, AddMeCyt, and ddeThd are potent anti-HBV agents in vitro.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2291664      PMCID： PMC171976          DOI： 10.1128/AAC.34.10.1986

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Immunosuppressive function of hepatitis B antigens in vitro: role of endoribonuclease V as one potential trans inactivator for cytokines in macrophages and human hepatoma cells.

Authors:  C Jochum; R Voth; S Rossol; K H Meyer zum Büschenfelde; G Hess; H Will; H C Schröder; R Steffen; W E Müller
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  The reporting of communicable diseases.

Authors:  R Marier
Journal:  Am J Epidemiol       Date:  1977-06       Impact factor: 4.897

4.  Inhibition of herpesvirus DNA synthesis by 9-beta-D-arabinofuranosyladenine in cellular and cell-free systems.

Authors:  W E Müller; R K Zahn; K Bittlingmaier; D Falke
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

5.  The phosphorylation of 3'-deoxy-3'-fluorothymidine and its incorporation into DNA in a cellfree system from tumor cells.

Authors:  P Langen; G Kowollik; G Etzold; H Venner; H Reinert
Journal:  Acta Biol Med Ger       Date:  1972

6.  Effect of vidarabine on chronic hepatitis B virus infection.

Authors:  R B Pollard; J L Smith; A Neal; P B Gregory; T C Merigan; W S Robinson
Journal:  JAMA       Date:  1978-04-21       Impact factor: 56.272

7.  Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses.

Authors:  E De Clercq
Journal:  Cancer Lett       Date:  1979-11       Impact factor: 8.679

8.  Potentiation of the cytostatic effect of bleomycin on L5178y mouse lymphoma cells by pepleomycin.

Authors:  W E Müller; M Geisert; R K Zahn; A Maidhof; M Bachmann; H Umezawa
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

9.  Synthesis of 6-substituted thymine nucleosides.

Authors:  M von Janta-Lipinski; P Langen
Journal:  Nucleic Acids Symp Ser       Date:  1981

10.  Cloned duck hepatitis B virus DNA is infectious in Pekin ducks.

Authors:  R Sprengel; C Kuhn; C Manso; H Will
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103
View more
  8 in total

1.  Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs.

Authors:  E Matthes; K Reimer; M von Janta-Lipinski; H Meisel; C Lehmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

2.  Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.

Authors:  E Matthes; A Funk; I Krahn; K Gaertner; M von Janta-Lipinski; L Lin; H Will; H Sirma
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

3.  Synthesis and evaluation of the anti-hepatitis B virus activity of 4'-Azido-thymidine analogs and 4'-Azido-2'-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

Authors:  Kengo Onitsuka; Ryoh Tokuda; Nobuyo Kuwata-Higashi; Hiroki Kumamoto; Manabu Aoki; Masayuki Amano; Satoru Kohgo; Debananda Das; Kazuhiro Haraguchi; Hiroaki Mitsuya; Shuhei Imoto
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2019-09-12       Impact factor: 1.381

4.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

5.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

6.  Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.

Authors:  S Balakrishna Pai; S H Liu; Y L Zhu; C K Chu; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine.

Authors:  J O Ojwang; B K Bhattacharya; H B Marshall; B E Korba; G R Revankar; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver.

Authors:  I Fourel; J Saputelli; P Schaffer; W S Mason
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.